Bristol-Myers Squibb (NYSE:BMY) Receives “Outperform” Rating from William Blair

William Blair reaffirmed their outperform rating on shares of Bristol-Myers Squibb (NYSE:BMY) in a report published on Monday, RTT News reports.

A number of other equities analysts also recently commented on BMY. JPMorgan Chase & Co. set a $62.00 price objective on Bristol-Myers Squibb and gave the stock a buy rating in a report on Friday, September 13th. UBS Group raised their price objective on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a neutral rating in a report on Wednesday, October 23rd. Bank of America began coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They set a buy rating and a $60.00 target price on the stock. ValuEngine downgraded Bristol-Myers Squibb from a sell rating to a strong sell rating in a report on Friday, October 25th. Finally, Atlantic Securities upgraded Bristol-Myers Squibb from a neutral rating to an overweight rating and set a $63.00 target price on the stock in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $57.45.

NYSE:BMY traded down $1.17 during mid-day trading on Monday, reaching $56.48. The company’s stock had a trading volume of 39,241,422 shares, compared to its average volume of 15,164,344. The company’s fifty day simple moving average is $54.34 and its two-hundred day simple moving average is $48.77. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. Bristol-Myers Squibb has a twelve month low of $42.48 and a twelve month high of $59.17. The stock has a market cap of $95.46 billion, a P/E ratio of 14.19, a P/E/G ratio of 1.36 and a beta of 0.71.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The firm had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the company earned $1.09 EPS. Sell-side analysts expect that Bristol-Myers Squibb will post 4.33 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 2.90%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the sale, the senior vice president now directly owns 74,471 shares in the company, valued at approximately $4,219,526.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now owns 31,963 shares in the company, valued at $1,807,827.28. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of BMY. Garrett Wealth Advisory Group LLC acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $26,000. Lenox Wealth Advisors LLC grew its position in shares of Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. grew its position in shares of Bristol-Myers Squibb by 101.2% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 327 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Bristol-Myers Squibb by 52.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 230 shares in the last quarter. Finally, 1 North Wealth Services LLC acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $41,000. Institutional investors own 82.87% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: What is the Fibonacci sequence?

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.